Results 91 to 100 of about 2,398,894 (298)

Castration‐resistant prostate cancer cells are addicted to the high activity of cyclin‐dependent kinase 2

Molecular Oncology, EarlyView.
We show that emergence of castration‐resistant prostate (CRPC) is associated with significant upregulation of cyclins that positively regulate cyclin‐dependent kinase 2 (CDK2) and concomitant downregulation of CDK4 cyclins. This renders CRPC cells dependent on the high activity of CDK2, and CDK2 inhibitors synergistically sensitize CRPC cells to both ...
Joyeeta Chatterjee, Alessia Marin, Shivani Yalala, Harri M. Itkonen   +3 more
wiley   +1 more source

Intracellular trafficking of new anticancer therapeutics: antibody–drug conjugates

, 2017
Muhammad Kalim,1 Jie Chen,1 Shenghao Wang,1 Caiyao Lin,1 Saif Ullah,1 Keying Liang,1 Qian Ding,1 Shuqing Chen,2 Jinbiao Zhan1 1Department of Biochemistry and Genetics, School of Medicine, 2Department of Pharmaceutical Analysis, College of Pharmaceutical
Ullah S, Lin C, Chen J, Wang S, Liang K, Kalim M, Ding Q, Chen S, Zhan JB   +8 more
core  

Supplementary Table S4 from Engineered anti-CD70 antibody-drug conjugate with increased therapeutic index

, 2008
Supplementary Table S4 from Engineered anti-CD70 antibody-drug conjugate with increased therapeutic ...
Eileen Turcott (15041066), Ivan Stone (15036102), Hans-Peter Gerber (4261570), Lori Westendorf (15036087), Charlotte F. McDonagh (14973178), Stephen C. Alley (1897735), Django Sussman (1934839), Martha Anderson (1934836), Paul J. Carter (3387371), Tiffany Feist (15036093), Jamie Miyamoto (15041069), Kristine M. Kim (15036084), Lindsay L. Brown (15036090), Robert Lyon (15036096)   +13 more
core   +1 more source

Mechanisms and therapeutic opportunities of the ribotoxic stress response in cancer

Molecular Oncology, EarlyView.
Cancer cells' high translational demand creates opportunities to therapeutically target ribosome function. Ribosome stalling and collisions activate ZAKα and the ribotoxic stress response (RSR), which can trigger rapid, p53‐independent apoptosis in cancer.
Anastassiya Kim, Maryam Aslam, Elouise Torruella, Alphons Sony, Asif Rahman, Simira Smith, Columba de la Parra, Moira Sauane   +7 more
wiley   +1 more source

Antibody-Drug Conjugate Sequencing in Metastatic Breast Cancer

healthbook TIMES. Oncology Hematology
Antibody-drug conjugates (ADCs) have redefined the therapeutic paradigm of metastatic breast cancer by combining targeted antibody specificity with potent cytotoxic payloads. The regulatory approvals of sacituzumab govitecan (SG), trastuzumab deruxtecan (
Benjamin Müller, Marcus Vetter
doaj   +1 more source

Supplementary Fig. S2 from Engineered anti-CD70 antibody-drug conjugate with increased therapeutic index

, 2008
Supplementary Fig.
Eileen Turcott (15041066), Ivan Stone (15036102), Hans-Peter Gerber (4261570), Lori Westendorf (15036087), Charlotte F. McDonagh (14973178), Stephen C. Alley (1897735), Django Sussman (1934839), Martha Anderson (1934836), Paul J. Carter (3387371), Tiffany Feist (15036093), Jamie Miyamoto (15041069), Kristine M. Kim (15036084), Lindsay L. Brown (15036090), Robert Lyon (15036096)   +13 more
core   +1 more source

Regulation of the lncRNA NEAT1 by p53‐ΔNp63 crosstalk modulates the DNA damage response and therapeutic efficacy in HNSCC

Molecular Oncology, EarlyView.
In head and neck squamous cell carcinoma (HNSCC) p53 and p63 exert opposite roles on the transcription regulation of the lncRNA NEAT1. Under basal conditions, p53 levels are low and p63 represses NEAT1 expression. Upon genotoxic stress, p53 is rapidly induced, displacing p63 from the NEAT1 promoter leading to NEAT1 transcriptional activation and ...
Sara De Domenico, Veronica La Banca, Silvia D'Amico, Stefano Scalera, Sara Nicolai, Angelo Peschiaroli   +5 more
wiley   +1 more source

Supplementary Material from Engineered anti-CD70 antibody-drug conjugate with increased therapeutic index

, 2008
Supplementary Material from Engineered anti-CD70 antibody-drug conjugate with increased therapeutic ...
Eileen Turcott (15041066), Ivan Stone (15036102), Hans-Peter Gerber (4261570), Lori Westendorf (15036087), Charlotte F. McDonagh (14973178), Stephen C. Alley (1897735), Django Sussman (1934839), Martha Anderson (1934836), Paul J. Carter (3387371), Tiffany Feist (15036093), Jamie Miyamoto (15041069), Kristine M. Kim (15036084), Lindsay L. Brown (15036090), Robert Lyon (15036096)   +13 more
core   +1 more source

Paclitaxel induces NM2‐dependent cellular contraction through GEF‐H1 dissociation from microtubules and RhoA/ROCK activation in cancer cells

Molecular Oncology, EarlyView.
Taxanes are widely used chemotherapeutics whose effects on cellular mechanics remain poorly understood. We show that paclitaxel induces rapid cellular contraction by promoting GEF‐H1 dissociation from microtubules and non‐muscle myosin II activation through RhoA/ROCK.
Gloria Asensio‐Juárez, Rafael Pérez‐Díaz, Hugo Ramos‐Solano, Marina Garrido‐Casado, Vanessa C. Talayero, Miguel Vicente‐Manzanares   +5 more
wiley   +1 more source

Prospective effect of linkers type on the anticancer activity of pemetrexed-monoclonal antibody (atezolizumab) conjugates [version 2; peer review: 2 approved, 1 approved with reservations]

F1000Research
Background Conventional chemotherapy results in severe toxic side effects due to affecting normal and cancer cells. The conjugation of chemotherapy with mAb will improve the chemotherapy selectivity towards cancer cells and at the same time will ...
Nidhal K. Maraie, Basma Talib Al-Sudani, Faten Q. Ibraheem, Ayad M.R. Raauf   +3 more
doaj   +1 more source